TransMedics Group (NASDAQ:TMDX) Announces Quarterly Earnings Results, Beats Expectations By $2.21 EPS

TransMedics Group (NASDAQ:TMDX) announced its quarterly earnings results on Tuesday. The company reported $2.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $2.21, FiscalAI reports. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The firm had revenue of $160.76 million for the quarter, compared to analysts’ expectations of $155.28 million.

TransMedics Group Price Performance

Shares of NASDAQ TMDX traded up $3.13 during trading on Tuesday, reaching $137.78. The company had a trading volume of 1,178,037 shares, compared to its average volume of 722,154. TransMedics Group has a 52 week low of $62.07 and a 52 week high of $156.00. The business’s 50 day moving average price is $132.73 and its 200-day moving average price is $126.05. The stock has a market cap of $4.71 billion, a PE ratio of 55.78 and a beta of 2.06. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Piper Sandler restated an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Morgan Stanley boosted their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, February 14th. Canaccord Genuity Group raised their price objective on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Finally, Needham & Company LLC lifted their target price on shares of TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $144.25.

Insider Buying and Selling

In related news, Director David Weill sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the transaction, the director owned 12,134 shares in the company, valued at $1,682,257.76. The trade was a 29.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Gerardo Hernandez sold 920 shares of the stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the completion of the transaction, the chief financial officer owned 15,064 shares in the company, valued at $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Harvest Fund Management Co. Ltd acquired a new stake in TransMedics Group in the third quarter worth $29,000. Allworth Financial LP increased its position in shares of TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after buying an additional 113 shares in the last quarter. Parallel Advisors LLC raised its stake in TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after buying an additional 83 shares during the period. US Bancorp DE lifted its holdings in TransMedics Group by 24.2% during the third quarter. US Bancorp DE now owns 533 shares of the company’s stock worth $60,000 after acquiring an additional 104 shares in the last quarter. Finally, Atlas Capital Advisors Inc. bought a new position in TransMedics Group during the fourth quarter worth about $61,000. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.